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SUmmAry – The aim of this study was to explore the role of inflammatory markers in the 
occurrence of depression. The concentrations of inflammatory markers were analyzed in the groups 
of healthy subjects and subjects with major depressive disorder (mdd) initially and after one-mon-
th antidepressant therapy in the latter. The intention was to demonstrate the role of inflammatory 
markers in the development of mdd by differences in their concentrations and to explain the mec-
hanism of depression development. This would help us expand our understanding of the occurrence 
of depression and enable introduction of some new methods in the treatment and diagnosis of depre-
ssion. Study results showed a statistically significant difference in the concentrations of inflamma-
tory markers (C-reactive protein (CrP), interleukin-6 and tumor necrosis factor alpha) between the 
group of mdd subjects and control group of healthy subjects. These concentrations were higher in 
mdd subjects. A statistically significant difference was also found in CrP concentration before and 
after antidepressant therapy administered to mdd patients, i.e. it was lower after antidepressant 
therapy. Study results pointed to the efficacy of antidepressant therapy for depression by reducing the 
concentration of this inflammatory marker.
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Introduction
integrative approach is the only currently possible 
and accepted in studying the etiology of major depres-
sive disorder1. Through integrative approach, i.e. in-
teraction of the genetic, other biological and psycho-
social factors, their joint influence in major depression 
has been recognized2. Growing evidence shows that 
immune modulators may play an important role in 
the pathophysiology of mood disorders or cause spe-
cific mood symptoms3-5. The immune system and the 
central nervous system create a two-way communica-
tion network6, and evidence for correlation between 
the immune system and mood disorders comes from 
two directions: disease associated symptoms such as 
sleepiness, feeling tired, weakness, losing appetite, 
etc., which all can be found in depression and can be 
connected to alteration in the immune system func-
tioning, while also being observed in most of general 
infectious states induced by different causes. most of 
these symptoms are mediated by the hypothalamus7,8. 
it is clear today that, besides immune reactions, im-
mune system is also included in the neuropathologic 
processes9. major depressive disorder (mdd) is a psy-
chiatric disorder that is presumed to be correlated with 
changes in the immune functioning10. maes et al. sug-
gest a model of major depression which implies that it 
is correlated with the activation of inflammatory re-
sponse11-14. According to this model or so-called ‘cy-
tokinetic hypothesis of depression’, major depression 
can be considered as a psychoneuroimmune disease in 
which peripheral immune activation (through omit-
ting inflammatory mediator) is responsible for numer-
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ous behavioral, neuroendocrine and neurochemical 
changes that are correlated with psychiatric state. The 
initial interest in cytokines in mood disorders was 
provoked by the occurrence of depressive symptoms 
observed in patients administered purified or recom-
binant cytokines as well as by the increase in the pe-
ripheral level of proinflammatory cytokines in mood 
disorders15. However, it remains unclear whether the 
increase in cytokines contributes to disorder devel-
opment or it occurs as a secondary sequel of disease. 
maes et al. have initially reported on the increase in 
plasma interleukin-1 (il-1) and il-6 concentrations 
in people suffering from mdd16. levine et al. report 
on a high concentration of il-1ß, low concentration 
of il-6 and normal level of tumor necrosis factor al-
pha (tnf-α) in cerebrospinal fluid of 13 inpatients 
with uncured depression in comparison with a group 
of healthy volunteers17. many studies report on ma-
jor depression to be correlated with the increase in 
circulating levels of cytokines or their soluble recep-
tors, including il-2, soluble il-2 receptors, il-1ß, 
il-1 receptor antagonist, il-6, soluble il-6 recep-
tors and interferon gamma (ifn-γ)11. However, not 
all researches are consistent. One of the limitations in 
measuring cytokine concentrations is that cell activity 
caused by cytokines also leads to the release of soluble 
receptors (which inhibit biological activity of cytok-
ines), although their circulating level does not influ-
ence functioning of the organ involved. in the same 
way, differences in the circulating concentrations of 
any specific cytokine between the subject groups need 
not be significant. 
immune modifications, including changes in il-6 
levels, have often been observed in mdd during 
treatment with selective serotonin reuptake inhibitors 
(SSris)18,19. Current literature lends further support 
to the view that major depression is associated with a 
proinflammatory response, as indicated by elevation in 
C-reactive protein (CrP) and cytokines such as il-6 
and tnf-α. Antidepressants suppress the inflamma-
tory response. most, although not all, studies support 
a link between depression and inflammation20,21. The 
aim of this study was to examine the possible differ-
ences and changes in the concentrations of proinflam-
matory cytokines il-6, tnf-α and CrP between 
the group of healthy subjects and group of subjects 
suffering from major depression before and after one-
month antidepressant treatment. The possible differ-
ences in il-6, tnf-α and CrP changes in subjects 




The study was conducted at University depart-
ment of Psychiatry, Sestre milosrdnice University 
Hospital Center in Zagreb during 2009 and 2010. 
The study included a control group of healthy subjects 
(n=36, 20 male and 16 female) and a group of subjects 
with major depression (n=38, 16 male and 22 female) 
treated at our outpatient department or as inpatients 
(stationary or day hospital). Control group consisted 
of students and employees of the department. They 
were clinically examined, laboratory analysis and psy-
chological assessment and testing were conducted, 
and they filled psychiatric scales for depression; thus 
the subjects not meeting the control group criteria 
were excluded.
The aim and purpose of the study were explained 
to all study participants and they signed the informed 
consent for participation in the study. Those who re-
fused to sign it were excluded, and so were patients 
with psychiatric or any other somatic comorbidity (di-
abetes, arterial hypertension, overweight, etc.). Study 
subjects were aged 25 to 55. 
Methods
The data important for the criteria of depression 
were collected by patient history and heterohistory 
(family and relatives). The possibility of ‘false-positive 
results’ was ruled out because we did not include pa-
tients with diagnoses and therapies that could influ-
ence the concentrations of inflammatory markers.
we used a structured questionnaire that consisted 
of sociodemographic and history variables, e.g., sex, 
age, family history of mdd, disease duration, disease 
episode duration, overall number of mdd episodes, 
time between the episodes, age at the first episode on-
set, and response to antidepressant pharmacotherapy. 
The patients meeting the mdd criteria accord-
ing to dSm-iV-tr22, additionally evaluated with 
the mini international neuropsychiatric interview 
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(mini)23 and Hamilton rating Scale for depres-
sion24, were included in the study and signed the in-
formed consent. Their blood samples were collected 
and then they were administered antidepressant ther-
apy (SSri; escitalopram, alfa-2 adrenergic antagonist, 
and mirtazapine, 5-Ht2A, 5-Ht2C and 5-Ht3 se-
rotonin receptor antagonist). blood samples were also 
collected from mdd patients after one month of an-
tidepressant therapy and the parameters listed below 
were analyzed. On each occasion, blood sampling was 
accompanied by clinical psychiatric assessment of de-
pression and therapy course (with questionnaires and 
scales). 
mini is based on dSm-iV-tr criteria and it was 
used to diagnose mdd and to exclude other psychi-
atric disorders. Using mini, we defined the subtype 
and complexity of mdd, the course of disorder and 
therapeutic response. we also used Hamilton rat-
ing Scale for depression, Hamilton rating Scale for 
Anxiety, Clinical Global impression (CGi), and psy-
chological assessment and testing.
blood samples from cubital vein for analysis of in-
flammatory markers were also obtained from control 
group. Study participants were asked to fast for 12 
hours and to rest for half an hour before blood sam-
pling. blood samples were collected in the morning, 
around 8.00 Am. Serum was separated by sample 
centrifugation, frozen and stored at -20 oC until de-
termination of inflammatory markers (il-6, tnf-α 
and CrP).
These inflammatory markers were determined 
when study patients presented for treatment, before 
antidepressant administration (day 0) and at 30 days of 
antidepressant therapy. On both occasions (day 0 and 
day 30), besides inflammatory markers, all the psychi-
atric scales described above were applied, so that we 
could compare the possible changes in inflammatory 
markers with psychic parameters on these scales. 
il-6 and tnf-α were determined by the auto-
mated eUrO/dPC chemiluminescence assay (di-
agnostic immulite Products Corporation, Gwynedd, 
Uk). Analytical sensitivity of the method is 1.7 pg/
ml for tnf-α and 2.0 pg/ml for il-6. The auto-
mated chemiluminescence procedure (dPC immulite 
device) has expanded diagnostic applicability of the 
results obtained. in the automated and computer-
ized procedure, all phases of determination are per-
formed in one reactive container. different antibodies 
are connected to the ball placed at the bottom of the 
reactive container. The device drops the determined 
volume of clinical sample into the reactive container. 
in this way, the antigen from the sample gets in touch 
with the suitable antibody connected to the ball. dur-
ing incubation, they connect to each other. This is fol-
lowed by rinsing with a buffer, along with fast rotation 
around the axis while the buffer is removed to the re-
spective chamber. Then another antibody marked with 
enzyme is added. After rinsing, luminogenic substrate 
is automatically added. The enzyme separates the sub-
strate by giving it a glowing chemical combination. 
The samples travel on a movable tape to the luminom-
eter reader. The results get printed. if the sample does 
not contain a tumor marker or the cytokine does not 
create an immunocomplex, the substrate added will 
not produce glowing in the reactive container.
CrP was determined on a beckman Coulter au-
toanalyzer (Olympus Optical Co., ltd., tokyo, Japan) 
by use of the immunoturbidimetric test for CrP level 
in human serum and plasma and reagents produced by 
beckman Coulter, inc., brea, CA, USA. 
testing procedure: when the sample is mixed with 
r1 reagent (buffer) and r2 reagent (antiserum solu-
tion), CrP reacts specifically with antihuman an-
tibodies to CrP to form insoluble aggregates. The 
absorption of these aggregates is proportional to the 
sample CrP concentration. beckman Coulter ana-
lyzers automatically calculate CrP concentration in 
the sample. The results are expressed in mg/l. The 
reference interval for adults is <5 mg/l.
Results
data were statistically analyzed with the SPSS 
for windows 8 software (Chicago, USA). The χ2-test 
and mann-whitney test were employed for nonpara-
metric data. Spearman correlation for nonparametric 
variables was used to analyze association between 
the concentrations of inflammatory markers (il-6, 
tnf-α and CrP) and values on Hamilton depres-
sion and anxiety scales before and after antidepressant 
therapy in the group of depressive patients. The level 
of statistical significance was set at 5% (p≤0.05).
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Table 1. Descriptive parameters and differences between 
control group (n=36) and group of major depressive disor-
























mwt = mann-whitney test; *p=statistical significance (p<0.05); m = 
mean; Sd = standard deviation
figure 1 shows serum CrP variable in the group of 
mdd patients on the day they presented to the hos-
pital and on day 30 of antidepressant therapy (marked 
with 2); CrP level was significantly lower (p=0.011) 
after antidepressant therapy. 
figure 2 shows serum il-6 variable in the group of 
mdd patients on the day they presented to the hospi-
tal and on day 30 of antidepressant therapy; there was 
no statistically significant difference between il-6 
level on day 0 and day 30 of antidepressant therapy 
(p=0.483).
figure 3 shows serum tnf-α variable in the 
group of mdd patients on the day they presented to 
the hospital and on day 30 of antidepressant therapy; 
there was no statistically significant difference be-
tween tnf-α level on day 0 and day 30 of antide-
pressant therapy (p=0.646).
figure 4 shows the Hamilton depression scale re-
sults in the group of mdd patients on the day they 
presented to the hospital and on day 30 of antidepres-
sant therapy; the results on the Hamilton depression 
scale were significantly lower after antidepressant 
therapy (p=0.01). 
figure 5 shows Hamilton anxiety scale results in 
the group of mdd patients on the day they presented 
to the hospital and on day 30 of antidepressant ther-







Fig. 1. C-reactive protein (CRp) in the group of major 
depressive disorder patients (n=38) on day 0 (1) and day 
30 of antidepressant therapy (2). 
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Fig. 2. Interleukin-6 (IL-6) in the group of major depres-
sive disorder patients (n=38) on day 0 (1) and day 30 of 
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Discussion
results of this study showed that there was a sta-
tistically significant difference in inflammatory mark-
ers (CrP, il-6 and tnf-α) between the group of 
mdd patients and control group of healthy subjects; 
these concentrations were higher in the former. for 
comparison, maes et al. report on the increase of il-6 
concentration in people with mdd16. levine et al. re-
port on low il-6 concentration and normal tnf-α 
level in the CSf of 13 inpatients with uncured de-
pression in comparison with a group of healthy vol-
unteers; however, their sample was very small17. There 
are other studies reporting on major depression to be 
correlated with an increase in the level of circulating 
cytokines or their soluble receptors, among them il-6 
and soluble il-6 receptors11. yoshimura et al. found 
that plasma levels of il-6 and tnf-α were sig-
nificantly higher in the depressed group than in the 
healthy control group25. 
A statistically significant difference was also found 
in the concentrations of the CrP inflammatory 
marker determined in mdd patients before and after 
antidepressant therapy. This difference suggests that 
Fig. 3. Tumor necrosis factor alpha (TNF-α) in the group 
of major depressive disorder patients (n=38) on day 0 (1) 
and day 30 of antidepressant therapy (2). 






Fig. 4. Hamilton depression scale results in the group of 
major depressive disorder patients (n=38) on day 0 (1) and 
day 30 of antidepressant therapy (2).








also significantly lower after antidepressant therapy 
(p=0.01). 
Fig. 5. Results on Hamilton anxiety scale in the group of 
patients with major depressive disorder (n=38) on day 0 








 1 Time 2
30 Acta Clin Croat,  Vol. 51,   No. 1,  2012
d. Crnković et al. Connection between inflammatory markers, antidepressants and depression
the inflammatory marker CrP, which was higher in 
mdd patients compared to control group and lower 
after than before antidepressant therapy in the former, 
has an important role in the etiology of depression, as 
also reported from other studies9,26,27. Our results are 
consistent with the “cytokine hypothesis” of depres-
sion9,28,29 and with some other studies15,16,20,21. The sig-
nificant difference in CrP indicates the importance of 
this acute phase inflammatory reaction protein as one 
of the very valuable and definite markers of depres-
sion. mdd is associated with some somatic diseases 
that are the leading cause of morbidity and mortality 
in the today’s world population. Previous researches 
have shown that the risk of cardiovascular and cere-
brovascular diseases, which cause and increase in-
flammation, is significantly higher in patients with 
depression than in healthy people30. Atherosclerosis is 
basically also an inflammatory process, so depression 
could be correlated with the risk of cardiovascular dis-
eases through the mechanism of elevated CrP as a 
marker of the low level system inflammatory reaction 
activity30. results of this study undoubtedly demon-
strated statistically significantly higher CrP levels in 
mdd patients as compared with the group of healthy 
subjects, suggesting that the previously described in-
flammatory process developed from the onset of the 
disease through continuously increased CrP. in this 
study, the factors associated with the possible CrP in-
crease in mdd subjects were excluded by differential 
diagnosis (connective tissue disease, carcinoma, myo-
cardial infarction, infection, systemic lupus erythe-
matosus, rheumatic arthritis, tuberculosis, rheumatic 
fever, bacterial pneumonia, pregnancy, etc.). So, the 
finding of increased CrP in mdd subjects referred 
to the possible mediating role of acute inflammatory 
reaction in the etiology of depression. Accordingly, it 
is valuable information that the patients’ CrP con-
centration was reduced after one month of antide-
pressant therapy and this result is definitely worth of 
further studying. in addition, increased levels of the 
inflammatory markers il-6 and tnf-α were mea-
sured in the group of mdd patients. Other studies 
have shown that proinflammatory cytokines (il-1, 
tnf-α and il-6) can influence mood and cognitive 
functions, thus contributing to anxiety, depression 
and helplessness31. Our results also speak in favor of 
these results. Analysis of serum CrP values in mdd 
patients on day 0 and day 30 of antidepressant therapy 
revealed that antidepressants significantly decreased 
CrP concentration, thus proving that antidepressants 
strongly inhibit this proinflammatory protein. if we 
try to define the mechanism of this action, the prob-
able answer would be modulation because antidepres-
sants cause changes in the neurotransmitter activity, 
thus influencing the proinflammatory markers in-
cluding CrP, as also suggested by maes32. CrP is an 
acute phase protein found in the blood and its blood 
level increases in response to inflammation. As mem-
ber of the group of inflammatory reaction acute phase 
reactants, the level of CrP rises constantly during the 
presence of inflammation in the body. This increase 
is associated with the increase in plasma level of il-
6, which is induced by macrophages. it grows above 
the normal values within six hours and reaches peak 
values within 48 hours. CrP is a marker of inflamma-
tory reaction and a useful indicator in the assessment 
of disease progress and therapeutic efficacy. 
we also studied the effect of escitalopram, a SSri, 
and mirtazapine, an alpha 2 adrenergic antagonist, 
and 5-Ht2A, 5-Ht2C and 5-Ht3 serotonin recep-
tor antagonist, considering that these two antidepres-
sants have in many ways different mechanisms of ac-
tion than those earlier described. Our study showed 
that the levels of the proinflammatory cytokines il-6 
and tnf-α were not changed one month after ther-
apy introduction. in order to explain these results, 
a wider context of the current knowledge about the 
etiology of depression should be observed33-35. Proin-
flammatory cytokines are strongly released from mac-
rophages in their activated form at the periphery and 
in the brain36. 
One-month antidepressant therapy led to some 
therapeutic results in terms of alleviation or partial re-
mission of the symptoms of depression, but the period 
must have been too short for the possible changes in 
the concentration of proinflammatory cytokines il-6 
and tnf-α to become evident. However, the decrease 
in the concentration of the proinflammatory CrP 
pointed not only to the importance of the mechanism 
of antidepressant action, but also to the possibility of 
interaction of anti-inflammatory cytokines. today, 
it is well known that many antidepressants increase 
the release of endogenous cytokine antagonists, such 
as antagonists of interleukin-1 receptor and interleu-
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kin-10 as anti-inflammatory cytokine4,21,33. evidence 
also shows that different kinds of antidepressants act 
as cyclooxygenase inhibitors, thus decreasing the con-
centration of inflammatory prostaglandins in the brain 
and the harmful influence of inflammatory changes 
on the neurotransmitter function. The overall sum of 
Hamilton scale values was significantly different in 
patients before and a month after the introduction of 
antidepressant therapy. early therapeutic response at 
one month of antidepressant therapy initiation was 
followed by a decrease in CrP concentration, objec-
tifying the partially positive inflammatory-immune 
response to antidepressant therapy through Hamilton 
depression and anxiety scales.
Conclusion
Our study results demonstrated a statistically 
significant difference in the levels of inflammatory 
markers (CrP, il-6 and tnf-α) between the group 
of mdd patients and control group of healthy sub-
jects; these concentrations were higher in the former. 
A statistically significant difference was also found in 
the concentrations of the inflammatory marker CrP 
before and after antidepressant therapy administered 
to mdd patients; CrP was lower after taking antide-
pressants. il-6 and tnf-α were not statistically dif-
ferent after one month of antidepressant therapy. The 
questions and conclusions ensuing from these results 
would certainly involve implications and use of the 
given knowledge. in other words, the question most 
frequently posed after this and similar studies is: can 
the inflammatory markers really be used as depend-
able and clear markers of depression, considering that 
they represent significant or even key factors in the 
etiology of depression? The answer is partially affir-
mative because diagnostic objectifying and clinically 
confirmed depression today represents a clear clinical 
entity considering the diagnostic methods currently 
available. Still, like biological markers, assessment of 
inflammatory markers can be additionally performed 
to confirm the diagnosis of depression, especially if 
the clinical symptoms and signals suggestive of de-
pression are insufficient to make the diagnosis of de-
pression based on diagnostic methods available. The 
present study demonstrated that the values of inflam-
matory markers differed between healthy subjects and 
subjects suffering from depression, thus providing 
evidence that additional diagnostic work-up can defi-
nitely include determination of inflammatory mark-
ers in patients suffering from depression. These results 
confirmed the efficacy of antidepressant therapy in 
the treatment of depression. The more so, our results 
pointed to the possible role of inflammatory markers 
in the etiology of depression, a very complex psycho-
pathological entity, where the interaction of external, 
genetic and biological factors leads to the development 
and manifestation of the disease.
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Sažetak
POVeZAnOSt UPAlniH bilJeGA, AntidePreSiVA i dePreSiJe
D. Crnković, D. Buljan, D. Karlović i M. Krmek
Cilj ovoga istraživanja bio je ispitati ulogu upalnih faktora u mehanizmu nastanka depresije. Analizirane su koncentra-
cije upalnih čimbenika između skupina zdravih ispitanika i ispitanika oboljelih od depresije pri dolasku i mjesec dana od 
početka liječenja antidepresivima u potonjoj skupini. temeljem razlika u koncentracijama navedenih čimbenika željelo se 
potvrditi njihovu ulogu u nastanku depresije i objasniti mehanizam nastanka depresije. time bi se uz proširivanje spoznaje 
o uzroku nastanka depresije mogle primijeniti i nove metode liječenja i dijagnostike depresije. Ovim radom pokazano je 
postojanje statistički značajne razlike u koncentracijama upalnih faktora (CrP, il-6 i tnf-α) između zdravih ispitanika 
i onih oboljelih od depresije. navedene koncentracije su bile više kod depresivnih ispitanika. nadalje, nakon terapije an-
tidepresivima zabilježena je statistički značajna razlika u koncentraciji CrP u odnosu na početak liječenja, tj. CrP je bio 
niži nakon terapije antidepresivima. dobiveni rezultati govore u prilog učinkovitosti terapijskog djelovanja antidepresiva u 
liječenju depresije kroz snižavanje koncentracije ovoga upalnog čimbenika.
ključne riječi: Depresija; Citokini; Mehanizam djelovanja antidepresiva

